Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Shrinking team NBB
FTE fell two years in a row, from 24.3 to 17.6.
-
Busy address KBO
20 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Ceres Pharmaceuticals from Gent, company number BE0407326754, closed financial year 2025 with a result of € 2.6 million after tax. For that financial year Ceres Pharmaceuticals recorded revenue of € 14.6 million and equity of € 1.3 million. Compared with financial year 2024, the result moved from € -99,159 to € 2.6 million. Profitable, and profit is growing. The buffer shrank hard: equity is 51 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.
€ 1.3 million
▼ 51% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 2.6 million
▲ still € 99,159 loss in 2024
Profit after tax over the fiscal year.
€ 39,350
▼ 97% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 4 million paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
17.6
▼ 6.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 2.4 million
▼ 9% vs 2024
€ 136,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 15,670
▼ 9% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 2.4 million
▲ 101% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 98 days on average.
€ 1.5 million
▲ 166% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 10,909,077 | € 10,605,465 | € 12,451,609 | € 14,578,548 | ▲ 17% |
| Profit after taxes | € 278,373 | € -300,447 | € -99,159 | € 2,637,004 | ▲ € 2.7 million |
| Equity | € 3,081,570 | € 2,781,123 | € 2,681,964 | € 1,318,968 | ▼ 51% |
| Total debts | € 1,553,891 | € 1,860,160 | € 2,047,828 | € 8,142,082 | ▲ 298% |
| Cash | € 461,326 | € 268,901 | € 1,163,703 | € 39,350 | ▼ 97% |
| Retained profit | € 2,081,570 | € 1,781,123 | € 1,681,964 | € 318,968 | ▼ 81% |
| Dividend | € 0 | € 0 | € 0 | € 4,000,000 | |
| Bank debt | € 139,660 | € 519,270 | € 3,175 | € 0 | ▼ 100% |
| Balance sheet total | € 4,635,462 | € 4,641,283 | € 4,729,792 | € 9,461,050 | ▲ 100% |
| Employees (FTE) | 23.4 | 24.3 | 23.9 | 17.6 | ▼ 6.3 |
Key figures of Ceres Pharmaceuticals, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Ceres Pharmaceuticals?
What happened at Ceres Pharmaceuticals in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Aquitania BV stepped down as director. NBB
- MD Consult BV stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 2.6 million. Source: NBB ↗
- Aquitania BV became a director. NBB
- MD Consult BV became a director. NBB
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
In short
From € 278,373 profit in 2022 to € 2.6 million profit in 2025.
Paid € 1.1 million in corporate taxes since 2022.
Best year ever: 2025, with € 2.6 million profit.
Paid out € 4 million in dividends to the owners in total.
Management
The stake of Ceres Pharma, KELA - Kempisch Laboratorium - Kela Laboratoria, VOXDALE comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Ceres PharmaceuticalsThe shares are held by Ceres Pharma (100%), KELA - Kempisch Laboratorium - Kela Laboratoria (99.9%) and VOXDALE (0.1%).
Directors
According to the 2025 annual accounts
Director · represented by Anja Imschoot
Also active at: VESALE PHARMACEUTICA, b+pharma Belgium, DGPharma, Labophar, 2PHARMA HOLDING, MD Pharma, GLOBIFER INTL, CREDOPHAR +1 more
since 2024 · until 2030
Director · represented by Mario Debel
Also active at: VESALE PHARMACEUTICA, 2PHARMA HOLDING, MD Pharma, Azur Medical, AUGMENTED ANATOMY, GLOBIFER INTL, CREDOPHAR, 2PHARMA
since 2024 · until 2030
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Kortrijksesteenweg 1091 box B
9051 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.
All companies at this address →What's Cooking Group
KOUTERLOS
€ 55,337 gross margin · 2024
b+pharma Belgium same network
€ 287,023 gross margin · 2025
DGPharma same network
€ 94,120 gross margin · 2024
Ceres Pharma same network
€ 35.3 million revenue · 2025
+15 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0407.326.754
- VAT number
- BE 0407.326.754
- Registered office
- Kortrijksesteenweg 1091 bus B, 9051 Gent
- Names & denominations
- Ceres Pharmaceuticals
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 23 September 1970
- Peppol
- Active · Active since 1 Aug 2025
- Activities · NACE
Groothandel in farmaceutische producten
Groothandel in farmaceutische en medische artikelen
Detailhandel in drogisterijartikelen en onderhoudsproducten
Gespecialiseerde detailhandel in drogisterijartikelen en onderhoudsproducten
Detailhandel in drogisterijartikelen en onderhoudsproducten in gespecialiseerde winkels